Abstract

Exploiting NGS and Liquid Biopsies For Clinical Individualized Neo-antigen Cancer Vaccines

John Castle, Senior Director, Agenus & 4-Antibody

We are treating cancer patients with individualized vaccines manufactured on-demand based on a NGS-profile of the patient tumor. We exploit NGS, bioinformatics, and computational immunology to generate the patient-specific vaccine blueprint. Our second-generation neoantigen vaccine platform, AutoSynVax™ (ASV™), entered the clinic in April and encodes mutation-containing peptides in a proprietary formulation and clinically tested adjuvant.